Pfizer Ends Pact With GlycoMimetics After SCD Failure
Rivipansel’s Sickle Cell Disease Trial Failure Triggered Pfizer’s Move
Executive Summary
GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.
You may also be interested in...
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group
Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…
Global Blood Therapeutics' Oxbryta Approved Broadly For Sickle Cell Disease
Oxbryta is the second new drug for sickle cell disease approved in just over one week, but it was approved with a broad label for sickle cell disease while Novartis' Adakveo was approved for pain crises.